Combined application of high resolution and tandem mass spectrometers to characterize methionine oxidation in a parathyroid hormone formulation

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1169-1179

  Pan, Changkang ^a   Valente, Joseph J ^a   Lobrutto, Rosario ^a   Pickett, Jennifer S ^a   Motto, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CNBr digestion; Drug product development; LC MS MS; Methionine oxidation; high resolution MS; Parathyroid hormone

Indexed keywords

CYANOGEN BROMIDE; METHIONINE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE FRAGMENT;

ARTICLE; DIGESTION; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; OXIDATION; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 76649088946     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21901     Document Type: Article

References (23)

1. Quattrocchi E, Kourlas H. 2004. Teriparatide: A review. Clin Ther 26:841-854.
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang OH, Mitlak BH. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
3. Whitfield JF. 2006. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it? Curr Opin Invest Drugs 7:349-359.
4. Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocana A, Bisello A, Hollis BW, Gundberg C, Stewart AF. 2006. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: A dose escalation study. Osteoporos Int 17:225-230.
5. Hilliker S, Wergedal JE, Gruber HE, Bettica P, Baylink DJ. 1996. Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 19:469-477.
6. Morley P, Whitfield JF, Willick GE. 2001. Parathyroid hormone: An anabolic treatment for osteoporosis. Curr Pharm Des 7:671-687.
7. Potts JT, Kronenberg HM, Rosenblatt M. 1982. Parathyroid-hormone- Chemistry, biosynthesis, and mode of action. Adv Protein Chem 35:323-396.
8. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. 2003. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212-5220.
9. Cosman F, Lindsay R. 1998. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62:475-480.
10. Wronski TJ, Yen CF, Qi H, Dann LM. 1993. Parathyroid-hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132:823-831.
11. Reginster JY, Burlet N. 2006. Osteoporosis: A still increasing prevalence. Bone 38:4-9.
12. Close P, Neuprez A, Reginster JY. 2006. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 7:1603-1615.
13. Sheridan C. 2008. Can 'double blockbuster' strengthen Amgen's backbone? Nat Biotechnol 26:361-363.
14. Lin JT, Lane JM. 2004. Osteoporosis-A review. Clin Orthop Relat Res 425:126-134.
15. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
16. Strickland LA, Bozzato RP, Kronis KA. 1993. Structure of human parathyroid hormone(1-34) in the presence of solvents and micelles. Biochemistry 32:6050-6057.
17. Klaus W, Dieckmann T, Wray V, Schomburg D, Wingender E, Mayer H. 1991. Investigation of the solution structure of the human parathyroidhormone fragment (1-34) by h-1-nmr spectroscopy, distance geometry, and molecular-dynamics calculations. Biochemistry 30:6936-6942.
18. Nabuchi Y, Fujiwara E, Kuboniwa H, Asoh Y, Ushio H. 1997. The stability and degradation pathway of recombinant human parathyroid hormone: Deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues. Pharm Res 14:1685-1690.
19. Nabuchi Y, Fujiwara E, Ueno K, Kuboniwa H, Asoh Y, Ushio H. 1995. Oxidation of recombinant human parathyroid hormone: Effect of oxidized position on the biological activity. Pharm Res 12:2049-2052.
20. Tashjian AH, Munson PL, Ontjes DA. 1964. Alkylation+oxidation of methionine in bovine parathyroid hormone-Effects on hormonal activity+ antigenicity. Biochemistry 3:1175-1182.
21. Rasmussen H, Craig LC. 1962. The parathyroid polypeptides. Recent Prog Horm Res 18:269-295.
22. Frelinger AL, Zull JE. 1984. Oxidized forms of parathyroid-hormone with biological-activity-Separation and characterization of hormone forms oxidized at methionine-8 and methionine-18. J Biol Chem 259:5507-5513.
23. Gross E, Witkop B. 1961. Selective cleavage of methionyl peptide bonds in ribonuclease with cyanogen bromide. J Am Chem Soc 83:1510-1511.